Drugs / TJ033721
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04900818 | Jun 2021 → Dec 2026 expected | biliary tract cancer, esophageal adenocarcinoma, gastric cancer, gastroesophageal cancer +2 | I-Mab Biopharma US Limited | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TJ033721 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04900818 ↗ |
| Known as | givastomig | “This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or...” NCT04900818 ↗ |